CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Escitalopram oxalate

Escitalopram oxalate

Last Updated: August 3, 2005

Result type: Reports

Project Number: SR0039-000

Product Line: Reimbursement Review

Generic Name: Escitalopram oxalate

Brand Name: Cipralex

Manufacturer: Lundbeck Canada Inc.

Therapeutic Area: Depression, Major Depressive Disorder (MDD)

Indications: Depression, Major Depressive Disorder (MDD)

Submission Type: Initial

Project Status: Withdrawn

Escitalopram oxalate

Files